Sienna Biopharm (NASDAQ:SNNA) CFO Richard D. Peterson purchased 7,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was acquired at an average cost of $15.00 per share, with a total value of $105,000.00. Following the transaction, the chief financial officer now directly owns 7,000 shares in the company, valued at $105,000. The purchase was disclosed in a filing with the SEC, which is available at this link.
Shares of Sienna Biopharm (SNNA) traded up 1.73% during trading on Friday, reaching $19.38. 76,768 shares of the company’s stock traded hands. Sienna Biopharm has a 1-year low of $18.50 and a 1-year high of $21.20.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Rincon Hill News and is owned by of Rincon Hill News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://rinconhillneighbors.org/2017/08/19/sienna-biopharmaceuticals-inc-nasdaqsnna-cfo-acquires-105000-00-in-stock-updated-updated.html.
Sienna Biopharm Company Profile
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with our FREE daily email newsletter.